Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mission Pharmacal has signed a patent and technology licensing agreement with EffRx Pharmaceuticals, for the manufacturing and commercialization of BINOSTO (alendronate sodium) effervescent tablets in the US and Canada.
Subscribe to our email newsletter
The FDA approved BINOSTO to treat osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis.
Utilizing EffRx’s formulation technology, BINOSTO is the first and only buffered effervescent therapeutic to deliver the gold standard in osteoporosis treatment and fracture prevention of alendronate sodium-in an easy-to-swallow, buffered solution.
Mission Pharmacal president Neil Walsdorf said: "We are very excited about our partnership with EffRx and look forward to helping deliver BINOSTO to women with osteoporosis who have difficulty with pills or shots and to men who also struggle with this disease."
EffRx CEO Christer Rosen added: "We believe Mission is the logical choice for bringing BINOSTO to the United States and Canadian markets. Mission is focused on quality first and foremost and they have a long history of educating patients and physicians in bone health."